FDC Limited Reports Q1 FY27 Results; Revenue Reaches Rs 668 Crores as International Formulations Drive Growth
FDC Limited has announced its unaudited financial results for the first quarter of Fiscal Year 2026-27, which ended on June 30, 2026. The company reported consolidated revenue from operations at Rs 668 crores for Q1 FY27.The financial performance shows moderate growth across key indicators. Revenue from Operations grew by 3.0%, reaching Rs 668 crores compared to Rs 648 crores in the corresponding quarter of Q1 FY26. EBITDA for Q1 FY27 stood at Rs 143 crores, reflecting a Y-o-Y increase of 1.9%. The EBITDA margin was recorded at 21.4%, down slightly from 21.6% in the previous fiscal year's quarter.
Profit before tax (PBT) increased by 9.4% year-over-year to Rs 175 crores. Profit after tax (PAT) saw a rise of 9.2% Y-o-Y, settling at Rs 132 crores. Earnings per share (EPS) stood at Rs 8.14, up from Rs 7.45 in Q1 FY26.
The consolidated financial figures for the quarter are presented below:
| Particulars | Q1 FY27 | Q1 FY26 | Y-o-Y Growth % |
|---|---|---|---|
| Revenue from Operations | 668 crores | 648 crores | 3.0% |
| EBITDA | 143 crores | 140 crores | 1.9% |
| EBITDA Margin | 21.4% | 21.6% | N/A |
| PBT | 175 crores | 160 crores | 9.4% |
| PAT | 132 crores | 121 crores | 9.2% |
| EPS (Rs.) | 8.14 | 7.45 | 9.2% |
Segment Performance and Business Updates
The company's business performance varied across its segments in Q1 FY27. Domestic Formulations contributed Rs 569 crores to revenue, representing a 3.0% increase year-over-year. However, the segment was impacted by subdued performance in select key brands, including Zifi, Enerzal, and Simyl MCT. Domestic Formulations accounted for approximately 85% of consolidated sales during the quarter. Secondary sales data from IQVIA showed growth of 9.0% for the quarter and 1.9% for the trailing twelve months (MAT).International Formulations generated Rs 73 crores in Q1 FY27, registering a significant Y-o-Y growth of 74.2%. This segment contributed approximately 11% to consolidated sales. The US business specifically reported revenue of Rs 34 crores, marking a dramatic Y-o-Y increase of 118.4%. Meanwhile, International Formulations from regions outside the US generated Rs 39 crores, growing by 47.7%. During this quarter, FDC received U.S. FDA approval for Cefixime for Oral Suspension USP 100mg/5mL and 200mg/5mL.
The APIs business recorded sales of Rs 24 crores in Q1 FY27, reflecting a decline of 2.9% year-over-year. This segment accounted for approximately 4% of consolidated sales.
Segmental revenue performance details are provided below:
| Segment | Revenue (Q1 FY27) | Y-o-Y Growth % |
|---|---|---|
| Domestic Formulations | Rs 569 crores | 3.0% |
| International Formulations (US) | Rs 34 crores | 118.4% |
| International Formulations (Non-US) | Rs 39 crores | 47.7% |
| APIs | Rs 24 crores | -2.9% |
FDC Stock Price Movement
Shares of FDC Limited today shed 4.18% to settle at ₹387.55, having dropped by ₹16.85 from its previous close. The equity traded within a narrow range during the session, hitting an intraday low of ₹381.10 as over 2.3 million shares were exchanged.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.